Addison's Disease: Symptoms, Diagnosis, Treatment, and Adrenal Crisis Prevention

What Exactly Is Addison's Disease?

Addison's disease, formally called primary adrenal insufficiency (PAI), is the irreversible loss of more than 90% of the adrenal cortex's hormone-secreting capacity. Both cortisol and aldosterone fall below physiological thresholds. Thomas Addison first described the syndrome in 1855 using post-mortem observations, and today population registries from Norway and the United Kingdom confirm a prevalence of 93, 140 per million [1]. Autoimmune adrenalitis accounts for 70 to 90% of cases in Western populations and is confirmed by measuring 21-hydroxylase antibodies [2].

Losing aldosterone separates Addison's disease from secondary adrenal insufficiency clinically. Aldosterone governs sodium retention and potassium excretion at the kidney. When it disappears, sodium spills into urine, plasma volume contracts, and potassium climbs. The result is postural hypotension, salt craving, and in severe cases, life-threatening hyperkalemia. Secondary adrenal insufficiency, which originates in the pituitary or hypothalamus, preserves aldosterone because the renin-angiotensin system remains intact.

The adrenal cortex also makes adrenal androgens, primarily dehydroepiandrosterone (DHEA) and its sulfate DHEA-S. Women with Addison's disease lose a significant androgen source and may report decreased libido and reduced pubic and axillary hair, symptoms that men with intact testes rarely experience as severely [3].

Recognizing the Symptoms: Why Addison's Disease Gets Missed

Fatigue is the presenting symptom in over 95% of patients, but it is non-specific. The constellation that should trigger a workup is fatigue combined with at least two of the following: unexplained weight loss, postural dizziness, salt craving, hyperpigmentation, nausea, or abdominal pain [4].

Hyperpigmentation is the most distinctive physical sign. ACTH and its precursor pro-opiomelanocortin (POMC) rise when cortisol feedback is lost, and ACTH binds melanocortin receptors in the skin. Darkening appears first at pressure points, palmar creases, recent scars, and the buccal mucosa. A patient can carry this sign for months before anyone connects it to adrenal disease. Vitiligo, conversely, co-occurs in roughly 10 to 20% of autoimmune Addison's cases [2].

Salt craving arises directly from aldosterone deficiency. Hyponatremia is present in approximately 88% of patients at diagnosis, and hyperkalemia in 64% [4]. These electrolyte shifts can cause muscle weakness, confusion, and cardiac arrhythmia if severe.

Gastrointestinal symptoms, including nausea, vomiting, and abdominal pain, are present in up to 50% of patients before diagnosis. Clinicians often chase a GI diagnosis for months before ordering morning cortisol.

How Addison's Disease Differs from Secondary Adrenal Insufficiency

Secondary adrenal insufficiency (SAI) stems from deficient ACTH secretion by the pituitary. The most common cause is exogenous glucocorticoid use suppressing the hypothalamic-pituitary-adrenal (HPA) axis. Doses of prednisone at or above 5 mg/day taken for more than three weeks carry meaningful suppression risk [5]. Other causes include pituitary tumors, Sheehan syndrome, traumatic brain injury, and cranial radiation.

Three clinical features differentiate SAI from PAI. First, hyperpigmentation is absent in SAI because ACTH is low, not high. Second, aldosterone function is preserved, so hyponatremia is milder and hyperkalemia is rare. Third, other pituitary hormones (TSH, LH, FSH, GH) may also be deficient, giving a clinical picture of panhypopituitarism rather than isolated adrenal failure.

The European Society of Endocrinology's 2016 clinical practice guideline states: "In secondary adrenal insufficiency, mineralocorticoid replacement is generally not required because the renin-angiotensin system remains intact." [6] This single distinction changes the treatment regimen entirely.

Diagnosing Addison's Disease: The Cosyntropin Stimulation Test

A random or 8 a.m. serum cortisol below 3 mcg/dL is virtually diagnostic of adrenal insufficiency. A value above 18 mcg/dL largely excludes it. Everything between 3 and 18 mcg/dL requires the 250 mcg cosyntropin (synthetic ACTH) stimulation test [6].

Protocol: draw baseline cortisol, inject 250 mcg cosyntropin IV or IM, redraw cortisol at 30 and 60 minutes. A peak cortisol below 18 mcg/dL confirms adrenal insufficiency. Sensitivity of the test for PAI approaches 97% [7]. For SAI, some guidelines prefer the insulin tolerance test or the 1 mcg low-dose cosyntropin test because partial ACTH deficiency may not fully suppress adrenal reserve.

Supporting labs include plasma ACTH, 21-hydroxylase antibodies, renin, aldosterone, and a complete metabolic panel. A morning ACTH above 100 pg/mL with a sub-stimulation cortisol confirms primary adrenal failure. An ACTH below 20 pg/mL in the same setting points to secondary or tertiary disease.

Adrenal CT is warranted when autoimmune antibodies are negative. Bilateral adrenal enlargement with calcification suggests granulomatous disease (tuberculosis, histoplasmosis). Bilateral hemorrhage can occur in sepsis (Waterhouse-Friderichsen syndrome) or in patients on anticoagulation [2].

Standard Treatment: Hydrocortisone and Fludrocortisone Dosing

Hydrocortisone is the preferred glucocorticoid for replacement because it is bioidentical to cortisol and its shorter half-life mimics the physiological diurnal rhythm better than prednisone or dexamethasone. The Endocrine Society's 2016 guideline recommends 15 to 25 mg/day divided into two or three doses, with the largest dose taken on waking [6]. A common regimen is 10 mg on waking, 5 mg at noon, and 5 mg at 4, 5 p.m. Doses taken after 6 p.m. disrupt sleep by elevating evening cortisol.

Fludrocortisone replaces aldosterone at 0.05 to 0.2 mg once daily, titrated to normalize upright plasma renin and resolve postural hypotension. Salt intake should be liberal, particularly in hot climates or during exercise. Many patients need extra sodium during summer months specifically, when sweat losses climb.

DHEA replacement is optional and not universally recommended, but a randomized crossover trial (N=39) found that DHEA 50 mg/day improved mood and quality of life scores in women with PAI at 12 weeks compared to placebo [3]. Men with intact testes generally have sufficient androgenic tone and derive less measurable benefit.

Over-replacement carries its own risks. Hydrocortisone doses consistently above 25 mg/day associate with reduced bone mineral density, hypertension, and glucose intolerance [8]. Annual DXA scanning and blood pressure monitoring are part of long-term management.

Adrenal Crisis: Recognition and Emergency Management

An adrenal crisis is a life-threatening acute deficiency of cortisol requiring immediate parenteral glucocorticoid. The European Adrenal Insufficiency Registry reported a crisis incidence of 6.3 events per 100 patient-years and a case fatality rate of 6% per crisis [9]. The crisis is triggered most often by intercurrent illness with vomiting, surgery without stress dosing, or missed oral medication.

Symptoms escalate rapidly. Nausea and abdominal pain give way to vomiting, then hypotension, then altered consciousness. Hypoglycemia, hyponatremia, and fever are common. In the absence of a medical-alert bracelet or a history obtained from a companion, clinicians may mistake the presentation for septic shock or an acute abdomen.

Treatment must not wait for laboratory confirmation. The American Association of Clinical Endocrinology recommends immediate IV or IM hydrocortisone 100 mg, followed by 200 mg over the next 24 hours by continuous infusion or 50 mg every 6 hours [10]. Simultaneous IV normal saline resuscitation corrects volume depletion. Glucose should be monitored and repleted. Fludrocortisone is unnecessary during acute treatment because hydrocortisone at 200 mg/day provides sufficient mineralocorticoid activity.

Every patient with known adrenal insufficiency should carry an emergency injection kit containing hydrocortisone 100 mg IM. The European Society of Endocrinology states: "All patients with adrenal insufficiency should be provided with an emergency glucocorticoid injection kit and be trained in its use." [6] Real-world data from Germany suggest that patient self-injection training cuts crisis hospitalization rates by 48% [9].

Sick-Day Rules: Dose Adjustments for Illness and Surgery

Physiological cortisol output rises three to ten times baseline during major physiological stress. Patients on fixed oral replacement cannot auto-adjust. Sick-day rules close this gap.

For fever above 38°C or significant illness, the standard instruction is to double or triple the daily hydrocortisone dose for the duration of the illness. If vomiting prevents oral intake for more than one hour, the patient self-injects 100 mg hydrocortisone IM immediately and contacts emergency services.

Surgical stress dosing follows a tiered protocol [6]:

• Minor procedures under local anesthesia: 25 mg hydrocortisone IV at induction
• Moderate surgery (e.g., cholecystectomy): 50 to 75 mg IV perioperatively, taper to usual dose over 1 to 2 days
• Major surgery or critical illness: 100 to 150 mg/day IV by continuous infusion, tapered as recovery allows

Dental procedures, colonoscopy with sedation, and minor imaging studies generally require only a one-time double oral dose, not parenteral medication. Endocrinologists should provide written protocols to surgeons, anesthesiologists, and emergency departments for every patient, because provider unfamiliarity with adrenal insufficiency is one of the most preventable causes of crisis death.

Cushing's Syndrome and Cushing's Disease: The Opposite End of the Cortisol Spectrum

Addison's disease and Cushing's syndrome sit at opposite poles of cortisol physiology, but they share the adrenal cortex as their anatomical battleground. Cushing's syndrome refers to any state of excess cortisol: exogenous glucocorticoids, an adrenal adenoma secreting cortisol autonomously, or an ectopic ACTH-secreting tumor (e.g., small-cell lung cancer).

Cushing's disease is a specific subtype: a pituitary corticotroph adenoma secreting excess ACTH, driving bilateral adrenal hyperplasia. Cushing's disease accounts for roughly 70% of endogenous Cushing's syndrome cases [11]. The National Institute of Diabetes and Digestive and Kidney Diseases reports an incidence of 10, 15 cases per million per year for all forms of Cushing's syndrome combined [11].

Clinically, Cushing's syndrome produces central obesity, dorsocervical and supraclavicular fat pads, proximal muscle weakness, wide purple striae, hypertension, hyperglycemia, and osteoporosis. These features contrast sharply with Addison's disease: weight loss rather than gain, hypotension rather than hypertension, hyperpigmentation rather than plethora.

Diagnosis of Cushing's syndrome begins with 24-hour urinary free cortisol, late-night salivary cortisol (two separate samples), or the 1 mg overnight dexamethasone suppression test. A post-dexamethasone 8 a.m. cortisol above 1.8 mcg/dL is a positive screen [11]. Confirming the source requires plasma ACTH, pituitary MRI, CRH stimulation test, and sometimes bilateral inferior petrosal sinus sampling.

Treatment for Cushing's disease is transsphenoidal pituitary adenomectomy, with remission rates of 65 to 90% at specialized centers [11]. Patients entering surgical remission are often transiently adrenal-insufficient for 6 to 18 months while suppressed adrenal tissue recovers, so they require hydrocortisone replacement during that window.

Long-Term Monitoring and Quality of Life in Addison's Disease

Addison's disease is lifelong. There is no immunosuppressive therapy that reliably restores adrenal function once destroyed, although experimental adrenal cell transplantation protocols remain in early-phase research. Annual monitoring includes plasma renin (target mid-normal range on standing sample), electrolytes, blood pressure, weight, and DXA bone density [6].

Quality of life (QoL) is persistently reduced relative to matched controls even when laboratory markers normalize. A 2016 cohort study of 1,245 patients with PAI reported significantly lower scores on the SF-36 physical and mental component summaries compared to age-matched population norms, with fatigue and reduced vitality as the dominant complaints [8]. Twice-daily modified-release hydrocortisone formulations, such as Plenadren (not yet widely available in the U.S.), may narrow this QoL gap by delivering a more physiological cortisol curve, according to a Phase III trial (N=64) that showed improved overall health status scores versus immediate-release hydrocortisone at 12 weeks [12].

The HealthRX clinical team stratifies Addison's disease management into three tiers based on crisis history and patient self-management capacity: Tier 1 (no prior crisis, trained in self-injection, low-risk occupation) follows standard monitoring every 12 months; Tier 2 (one prior crisis or incomplete self-injection training) schedules follow-up every 6 months and involves an emergency department notification letter; Tier 3 (two or more crises in 24 months, or adherence concerns) moves to a shared-care model with monthly telehealth check-ins and a home health aide crisis plan. This framework has not been validated in prospective trials but reflects published guideline thresholds and clinical consensus.

Patients with autoimmune Addison's disease have a 50% lifetime risk of developing a second autoimmune condition, most commonly autoimmune thyroid disease (Hashimoto or Graves), type 1 diabetes, or premature ovarian insufficiency [2]. Annual thyroid function tests and periodic screening for celiac disease are standard components of follow-up.

When to Suspect Addison's Disease and Initiate Evaluation

A serum cortisol below 3 mcg/dL drawn between 7 and 9 a.m. warrants same-day endocrinology referral. Providers should not wait for a specialist appointment before ordering confirmatory tests. The cosyntropin stimulation test can be arranged by a primary care provider, the result returned within 2 hours, and empirical hydrocortisone started if the clinical picture is compelling and crisis feels imminent.

The delay from symptom onset to diagnosis averages 2.5 years in retrospective series, largely because fatigue and weight loss are attributed to depression, malignancy, or chronic fatigue before adrenal disease is considered [4]. Checking 8 a.m. serum cortisol adds one tube to a routine morning draw and costs less than most imaging studies ordered for the same symptom complex.

Any patient presenting to an emergency department with unexplained hypotension, hyponatremia, and hyperpigmentation should receive empirical hydrocortisone 100 mg IV immediately. Waiting for a cosyntropin result in an unstable patient is not appropriate.

For patients already diagnosed and stabilized on replacement therapy, the most important clinical instruction is this: if you cannot take oral medication because of vomiting, inject 100 mg hydrocortisone IM into the outer thigh and call emergency services. That single action has a documented survival benefit.